ABSTRACT
Objective:
To observe the
clinical efficacy of modified Erchentang on
CXC chemokine ligand receptors (CXCR1/2)and their
ligands CXCL8,
macrophage inflammatory protein -2(MIP-2) in
patients of
chronic obstructive pulmonary disease(AECOPD)at acute exacerbation stage,and assess the effect and mechanism of modified Erchentang on anti-inflammatory in
patients of AECOPD.
Method:
This study was a multicenter, randomized single blind, controlled trial. The authors selected 200 cases in conformity to the
standards of AECOPD. The AECOPD
patients were randomly divided into modified Erchentang group and
control group. In addition to the western
medicine, modified Erchentang was also given to the modified Erchentang group, and Jizhitangjiang was given to the
control group for 14 days. Each group was observed for the alleviation of the symptoms. Euzyme-linked
immunosorbent assay (
ELISA) was used to determine the levels of CXCL8 and MIP-2 in the
patients'
plasma of all groups before and
after treatment.
Western blot were used to detect the levels of CXCR1, CXCR2 and CXCL8
protein in
peripheral blood mononuclear cells(PBMCs).
Immunocytochemistry (ICC)
method was used to detect the expressions of CXCL8, CXCR1 and
CXCR2 protein in PBMCs.
Result:
The level of CXCL8 in
plasma, and the expressions of CXCR1, CXCR2 and CXCL8
mRNA and
protein in the modified Erchentang group were decreased significantly than those in the
control group(PP
Conclusion:
Modified Erchentang has an anti-inflammatory effect on AECOPD. Its mechanism may be related to the
down-regulation of the expressions of CXCL8, CXCR1 and CXCR2, the reduction of synthesis and release of CXCL8 and MIP-2, the inhibition of the
chemotaxis and activity of inflammatory
cells, and the prevention of
inflammation progress.